title: Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide.
abstract: One hundred and one patients participating in a phase I study with the synthetic retinoid 4-HPR (4-hydroxyphenyl retinamide) were evaluated. The study was set up by Veronesi et al. during 1986 at the National Cancer Institute of Milan. The patients were randomized into 4 groups of therapy: 25 in the placebo group, 25 in the group receiving a daily dose of 100 mg of HPR, 26 in the group receiving 200 mg/day of HPR, and 25 in the group receiving 300 mg/day of HPR. All patients were previously treated at our Institute for breast cancer. None had received adjuvant therapy, chemotherapy or hormone therapy. After 4-5 months from the beginning of treatment, all patients received a series of tests to evaluate anxiety, depression and sexual life. Moreover, during one the follow-up checkups after 4-5 months, the patients filled-out a self-scoring mood questionnaire. The results did not show any particular differences between the groups, although we found that the administered drug and experimental setting do not interfere with the psychologic state of the participating patients.
authors.affiliation: Terapia del Dolore, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano.
authors.forename: A
authors.initials: A
authors.lastname: Filiberti
authors.forename: M
authors.initials: M
authors.lastname: Tamburini
authors.forename: C
authors.initials: C
authors.lastname: Andreoli
authors.forename: F
authors.initials: F
authors.lastname: Buranelli
authors.forename: T
authors.initials: T
authors.lastname: Campa
authors.forename: A
authors.initials: A
authors.lastname: Costa
authors.forename: G
authors.initials: G
authors.lastname: Dossena
authors.forename: A
authors.initials: A
authors.lastname: Magni
authors.forename: M
authors.initials: M
authors.lastname: Pizzichetta
authors.forename: V
authors.initials: V
authors.lastname: Ventafridda
mesh_terms: D000223:Adaptation, Psychological; D000328:Adult; D000339:Affect; D001007:Anxiety; D001943:Breast Neoplasms / Q000517:prevention & control / Q000523:psychology*; D003863:Depression; D004341:Drug Evaluation; D005260:Female; D017313:Fenretinide; D006801:Humans; D008875:Middle Aged; D011897:Random Allocation; D012725:Sexual Behavior; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D017313:Fenretinide; D014212:Tretinoin